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Inflammation is the natural defense mechanism within the human body to combat and eliminate hazardous stimuli,
such as irritants, pathogens and damaged cells. Although inflammation can be beneficial in the resolution of injury,
chronic inflammation is a concern, as chronically inflamed tissues often amplify the inflammatory response by
recruiting immune cells from the bloodstream, leading to excessive self-targeted aggressiveness that results in
disease. With respect to the respiratory system, excessive airway inflammation is the hallmark of various CRDs,
including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and acute respiratory distress
syndrome [1,2]. CRDs are among the main contributors to major public health burdens as they account for a
significant proportion of global morbidity and mortality, thereby warranting the development of new targeted
therapeutic approaches to tackle the increasing impact brought by these diseases. PI3Ks are one of the main families
of kinases that play a central role in mediating signaling cascades that lead to the initiation and maintenance of
inflammatory responses. As aberrant PI3K signaling can result in the development of CRDs, the selective targeting
of individual PI3K isoforms is a promising therapeutic approach for the regulation of immune responses [3].
Nanomaterials offer great prospects to be developed as advanced and versatile drug delivery platforms targeting
PI3K signaling in the treatment of CRDs owing to their unique physicochemical properties, at the same time, they
have been shown to improve the pharmacokinetics of existing therapeutics [4,5]. This commentary describes the
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roles of PI3Ks in the pathogenesis of CRDs and the applications of advanced drug delivery systems in targeting
PI3K signaling for the management of CRDs.
PI3Ks & their signaling pathways
PI3Ks are intracellular signaling proteins involved in a myriad of cellular events and they have been widely
considered as potential targets in the treatment of various human diseases. The PI3K family can be divided into
three subtypes depending on their structure, namely classes I, II and III. Class I PI3Ks can be further classified
into class IA which comprises of isoforms PI3Kα, PI3Kβ and PI3Kδ, as well as class IB which comprises of the
PI3Kγ isoform. While the roles of classes II and III PI3Ks in inflammatory responses are currently not fully
understood, many studies have reported that class I PI3Ks play central roles in multiple steps of the inflammatory
cascades. Structurally, class I PI3Ks exist as heterodimeric complexes where p110, a catalytic subunit, is associated
with a particular regulatory subunit, such as p85, p55, p50, p101, and p84 [6,7]. Upon activation by cell surface
receptors such as insulin, growth factors and G-protein-coupled receptors (GPCRs), class I PI3Ks initiate signaling
pathways by phosphorylating phosphoinositol lipids at the D-3 position of the inositol ring, which then converts
phosphatidylinositol-4,5-biphosphate (PI-4,5-P2) into phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-P3) that
acts as a second messenger in the recruitment of cytosolic signaling proteins possessing pleckstrin homology
domains to specific locations within the plasma membrane or endomembrane. Representative effectors of class
I PI3Ks include protein serine/threonine kinases (protein kinase B/Akt), protein kinase C, PDK1 and MAPK.
In summary, PI3K is regarded as a hub in which signals are first relayed prior to specialization into secondary
signaling [6–8].
Significance of PI3Ks in CRDs
Asthma is an example of a CRD characterized by airway hyper-responsiveness and inflammation, with an increased
expression of cytokines, chemokines, growth factors and adhesion molecules, as well as enzymes. Typically, exposure
to allergens induces Th2 differentiation of T cells which leads to release of cytokines that promote allergic
inflammation. It has been demonstrated that class I PI3Ks are involved in the activation, differentiation and
proliferation of T cells, with PI3Kδ and PI3Kγ being the predominant isoforms. Upon engagement of T cell
receptor by antigens, PI3Kδ will be activated by tyrosine kinase signaling cascades; at the same time, PI3Kγ will
be recruited by the activation of G proteins via GPCRs and chemokine receptors [7,9]. PI3Ks are also involved in
mediating airway smooth muscles and epithelial cell responses. The contraction of airway smooth muscles and
accumulation of contractile proteins are typically modulated by the activation of PI3K via the regulation of Rho
kinase. Further, the secretion of IL-6 by airway smooth muscles is regulated by PI3K, in which IL-6 is a cytokine
central to airway remodeling and development of airway hyper-responsiveness in the pathogenesis of asthma [9].
In addition, PI3Kδ promotes the expression of IL-17 via the regulation of NF-κB signaling cascade, as proven
in the study by Park et al., which reported that airway inflammation and hyper-responsiveness were attenuated
by the suppression of PI3Kδ [10]. Increased eosinophils leading to induction of pro-inflammatory cytokines, Th2
cytokines, chemokines and reactive oxygen species (ROS) is another key feature of asthma, whereby it has been
found that inhibition of PI3Kγ suppresses eosinophil chemotaxis. This has been proven in multiple studies which
demonstrated that PI3K inhibition led to reduced eosinophilia and airway hyper-responsiveness in models of
allergen challenge. Studies also revealed that both PI3Kδ and PI3Kγ are responsible for the activation of mast cells,
in which they function in cascade with PI3Kδ acting as the initial response to IgE, followed by PI3Kγ to maximize
degranulation [7,9,11]. In summary, PI3K is a crucial signaling molecule that is involved in almost all aspects of
asthma pathogenesis, thus, inhibition of PI3K may be therapeutically advantageous as it can prevent mast cell
degranulation, inhibit the recruitment of immune cells, suppress mucus hyperproduction, as well as to facilitate
bronchodilation.
A similar strategy can also be employed to manage other inflammatory CRDs, such as COPD. In contrast to
asthma, chronic inflammation in COPD primarily involves Th1-induced neutrophils and macrophages. It has been
established that PI3K signaling is strongly induced in COPD and it is correlated with increased susceptibility to
lung infection. Studies have also reported that PI3K activation is necessary for the migration of neutrophils and
infiltration of monocytes into the lung. Moreover, the release of ROS in neutrophils is found to be dependent on
the activation of both PI3Kγ and PI3Kδ in a biphasic manner [8,12]. Cystic fibrosis is another example of a CRD
which is a result of a mutation in the gene responsible for encoding cystic fibrosis transmembrane conductance
regulator. In cystic fibrosis, the lungs of patients may rapidly develop inflammation characterized by an influx of
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polymorphonuclear cells, which is correlated with an imbalance between anti- and pro-inflammatory mediators.
As the ability of PI3Kδ and PI3Kγ in modulating the influx of pro-inflammatory mediators has been widely
documented in the inflammatory models of asthma and COPD, specific targeting of these PI3K isoforms may be
exploited as an alternative management approach in the management of cystic fibrosis [8,13].
Applications of advanced drug delivery systems
Due to the involvement of PI3Ks in immune responses, isoforms of PI3Ks and their signaling pathways have
been explored as promising targets in the design and development of therapeutics for the management of CRDs.
Although various PI3K-targeted compounds have been developed, some of them face limitations including poor
bioavailability and pharmacokinetic variability, incidences of adverse reactions, as well as poor targeting ability.
In recent years, the development of advanced drug delivery systems using nanomaterials has gained significant
attention due to their potential for targeted delivery and their sustained release profile when compared with
unconjugated compounds. Nanotechnological advancements have allowed surface functionalization of site-selective
ligands, which can further improve targeting toward specific PI3K isoform while enhancing the cellular uptake,
bioavailability, biodistribution and biocirculation time of loaded compounds. Nanomaterials may also possess
intrinsic biological activities that offer synergistic benefits along with those of the loaded compounds. Overall,
utilization of advanced drug delivery systems is highly beneficial in the development of novel therapeutics targeting
PI3K signaling in CRDs, as it allows customization where the engineering of such nanovehicles can be tailored to
meet specific applications [5,14,15].
There have been multiple studies performed in recent years to evaluate the feasibility of advanced drug delivery
systems in targeting PI3Ks for managing CRDs. A study by de Oliveira et al. formulated resveratrol (RSV)-
loaded lipid-core nanocapsules (RSV-LNCs) composed by biodegradable polymers to evaluate their efficacy in
attenuating acute lung injury. It was reported that RSV-LNCs remarkably improved lung function by preventing
the accumulation of leucocytes and neutrophils in the lung tissue via blockade of the PI3K/Akt signaling pathway.
Conversely, unloaded RSV was found to be ineffective in preventing the production of pro-inflammatory cytokines
in lung tissues [16]. Similarly, Gholizadeh et al. loaded dactolisib, a potent class I PI3K inhibitor into polymeric
nanoparticles and evaluated their anti-inflammatory potential. It was demonstrated that the nanoparticles could
effectively deliver dactolisib to TNF-α activated cells, suggesting that they can be developed as novel therapeutics
for inflammatory CRDs by targeted inhibition of PI3Ks [17]. Further, Jang et al. investigated the effects of silver
nanoparticles on mucus hyperproduction, which is a key feature in allergic airway inflammation. Results indicated
that the administration of silver nanoparticles significantly reduced the expressions of PI3Ks in lung tissues,
which led to the suppression of mucus hyperproduction via the downregulation of PI3K/HIF-1α/VEGF signaling
pathway [18]. On the other hand, Poerio et al. developed liposomes loaded with phosphatidylinositol-5-phosphate
(PI-5-P) and evaluated their potential in limiting tissue-damaging inflammatory response in cystic fibrosis associated
infections [19]. PI-5-P is a second messenger that promotes bacterial phagocytosis by modulating the PI3K/Akt
signaling pathway. The results showed that the liposomes remarkably downregulated NF-κB and the production of
IL-1β, IL-6 and TNF-α. The infiltration of pulmonary neutrophils was also remarkably reduced, while enhancing
bacterial uptake, phagosome acidification and intracellular bacterial killing in cystic fibrosis macrophages. Taken
together, these findings suggest that liposomal nanovehicles enable a targeted approach in enhancing phagocytosis
and ameliorate chronic inflammatory response in cystic fibrosis patients [19]. Furthermore, a recent study by
Pooladanda et al. engineered iRGD peptide-conjugated liposomes loaded with nimbolide (iRGD-NIMLip), an
anti-inflammatory phytomedicine, in treating acute respiratory distress syndrome, which shares many of the clinical
manifestations as those associated with the recent outbreak of the COVID-19 [20]. It was reported that iRGD-
NIMLip attenuated lipopolysaccharide-induced expressions of inflammatory genes via the PI3K/Akt/mTOR
signaling pathway. Oxidative stress and cytokine storm were also remarkably suppressed by iRGD-NIMLip in
contrast to free nimbolide. Thus, these findings suggest that advanced drug delivery system can be employed
as novel therapeutics targeting chronic lung inflammation and other pathological consequences associated with
COVID-19 and other CRDs [20].
Conclusion
Although PI3Ks regulate various key processes in the inflammatory responses of human body against damage
and infections, dysregulated PI3K signaling in the lung tissues may lead to augmented self-perpetuating damage,
resulting in the development of CRDs. Advanced nano-based drug delivery systems have the potential to be
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employed as both therapeutics and vectors in the management of CRDs via PI3K-targeted approaches, as they
possess multiple key advantages attributed to their unique physicochemical characteristics as compared with those
of conventional therapeutics. Additionally, modern nanotechnological approaches allow for surface and structural
functionalization of drug delivery systems, thereby enhancing their targeting capability and therapeutic efficacies.
Unfortunately, to date, the studies conducted in this area of research remain relatively scarce. Hence, more in-depth
studies should be performed to elucidate the exact targeting mechanisms involved, which allows for future clinical
translation of safe and effective novel therapeutics in the management of CRDs.
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